Kim and colleagues (105) found that EP-100 rapidly destroyed the cell membrane and increased PD-L1 levels after specific binding to ovarian cancer cells, and observed that EP-100 increased anti-tumor effector T cells and IL33 expression and induced anticancer activity in vivo when EP-100 and anti-PD-L1 antibodies were combined. Here, CD274 is linked to ovarian cancer.